Chinese female breast cancer patients show a better overall survival than their male counterparts

Chinese Medical Journal

Volumn 123, Issue 17, 2010, Pages 2347-2352

  Xia, Liang Ping ^a   Zhou, Fei Fei ^a,b   Guo, Gui Fang ^a   Wang, Fang ^a   Wang, Xi ^a   Yuan, Zhong Yu ^a   Zhang, Bei ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b Tumor Center First People's Hopsital of Foshan Foshan   (China)

Author keywords

Female breast cacer; Male breast cancer; Postmenopausal; Prognosis

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CHINESE; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MASTECTOMY; OVERALL SURVIVAL; POSTMENOPAUSE; PROGNOSIS; PROTEIN EXPRESSION; SEX DIFFERENCE; SURVIVAL RATE;

ADULT; AGED; BREAST NEOPLASMS; BREAST NEOPLASMS, MALE; CHINA; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SEX CHARACTERISTICS; SURVIVAL RATE;

EID: 79851469555     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2010.17.012     Document Type: Article

References (38)

1. Anderson WF, Althuis MD, Brinton LA, Devesa SS. Is male breast cancer similar or different than female breast cancer? Breast Cancer Res Treat 2004; 83: 77-86.
2. Malani AK. Male breast cancer: a different disease than female breast cancer? South Med J 2007; 100: 197.
3. Thalib L, Hall P. Survival of male breast cancer patients: population-based cohort study. Cancer Sci 2009; 100: 292-295.
4. Park S, Kim JH, Koo J, Park BW, Lee KS. Clinicopathological characteristics of male breast cancer. Yonsei Med J 2008; 49: 978-986.
5. Hill TD, Khamis HJ, Tyczynski JE, Berkel HJ. Comparison of male and female breast cancer incidence trends, tumor characteristics, and survival. Ann Epidemiol 2005; 15: 773-780.
6. Marchal F, Salou M, Marchal C, Lesur A, Desandes E. Men with breast cancer have same disease-specific and event-free survival as women. Ann Surg Oncol 2009; 16: 972-978.
7. Neumayer L, Schifftner TL, Henderson WG, Khuri SF, El-Tamer M. Breast cancer surgery in Veterans Affairs and selected university medical centers: results of the patient safety in surgery study. J Am Coll Surg 2007; 204: 1235-1241.
8. Anan K, Mitsuyama S, Nishihara K, Abe Y, Iwashita T, Ihara T, et al. Breast cancer in Japanese men: does sex affect prognosis? Breast Cancer 2004; 11: 180-186.
9. El-Tamer MB, Komenaka IK, Troxel A, Li H, Joseph KA, Ditkoff BA, et al. Men with breast cancer have better disease-specific survival than women. Arch Surg 2004; 139:1079-1082.
10. Meijer-van Gelder ME, Look MP, Bolt-de Vries J, Peters HA, Klijn JG, Foekens JA. Clinical relevance of biologic factors in male breast cancer. Breast Cancer Res Treat 2001; 68: 249-260.
11. Scott-Conner CE, Jochimsen PR, Menck HR, Winchester DJ. An analysis of male and female breast cancer treatment and survival among demographically identical pairs of patients. Surgery 1999; 126: 775-780.
12. Borgen PI, Senie RT, McKinnon WM, Rosen PP. Carcinoma of the male breast: analysis of prognosis compared with matched female patients. Ann Surg Oncol 1997; 4: 385-388.
13. Willsher PC, Leach IH, Ellis IO, Bourke JB, Blamey RW, Robertson JF. A comparison outcome of male breast cancer with female breast cancer. Am J Surg 1997; 173: 185-188.
14. Nahleh ZA, Srikantiah R, Safa M, Jazieh AR, Muhleman A, Komrokji R. Male breast cancer in the veterans affairs population: a comparative analysis. Cancer 2007; 109: 1471-1477.
15. Giordano SH, Cohen DS, Buzdar AU, Perkins G, Hortobagyi GN. Breast carcinoma in men: a population-based study. Cancer 2004; 101:51-57.
16. Levi F, Randimbison L, La Vecchia C. Breast cancer survival in relation to sex and age. Oncology 1992; 49: 413-417.
17. André S, Pinto AE, Laranjeira C, Quaresma M, Soares J. Male and female breast cancer-differences in DNA ploidy, p21 and p53 expression reinforce the possibility of distinct pathways of oncogenesis. Pathobiology 2007; 74: 323-327.
18. Yang MT, Rong TH, Huang ZF, Zeng CG, Long H, Fu JH, et al. Clinical analysis of resectable breast cancer: a report of 6263 cases. Cancer (Chin) 2005; 24: 327-331.
19. Mouridsen HT, Bjerre KD, Christiansen P, Jensen MB, Møller S. Improvement of prognosis in breast cancer in Denmark 1977-2006, based on the nationwide reporting to the DBCG Registry. Acta Oncol 2008; 47: 525-536.
20. Cutuli B. Strategies in treating male breast cancer. Expert Opin Pharmacother 2007; 8: 193-202.
21. Contractor KB, Kaur K, Rodrigues GS, Kulkarni DM, Singhal H. Male breast cancer: is the scenario changing. World J Surg Oncol 2008; 6: 58.
22. Fentiman IS, Fourquet A, Hortobagyi GN. Male breast cancer. Lancet 2006 18; 367: 595-604.
23. Gennari R, Curigliano G, Jereczek-Fossa BA, Zurrida S, Renne G, Intra M, et al. Male breast cancer: a special therapeutic problem. Anything new? (Review). Int J Oncol 2004; 24: 663-670.
24. Satram-Hoang S, Ziogas A, Anton-Culver H. Risk of second primary cancer in men with breast cancer. Breast Cancer Res 2007; 9: R10.
25. Cutuli B, Lacroze M, Dilhuydy JM, Velten M, De Lafontan B, Marchal C, et al. Male breast cancer: results of the treatments and prognostic factors in 397 cases. Eur J Cancer 1995; 31A: 1960-1964.
26. Guinee VF, Olsson H, Moller T, Shallenberger RC, van den Blink JW, Peter Z, et al. The prognosis of breast cancer in males. A report of 335 cases. Cancer 1993; 71: 154-161.
27. Donegan WL, Redlich PN, Lang PJ, Gall MT. Carcinoma of the breast in males: a multiinstitutional survey. Cancer 1998; 83: 498-509.
28. Rudlowski C, Friedrichs N, Faridi A, Füzesi L, Moll R, Bastert G, et al. Her-2/neu gene amplification and proteinexpression in primary male breast cancer. Breast Cancer Res Treat 2004; 84: 215-223.
29. Tiezzi DG, Andrade JM, Ribeiro-Silva A, Zola FE, Marana HR, Tiezzi MG. HER-2, p53, p21 and hormonal receptors proteins expression as predictive factors of response and prognosis in locally advanced breast cancer treated with neoadjuvant docetaxel plus epirubicin combination. BMC Cancer 2007; 7: 36.
30. Bentel JM, Birrell SN, Pickering MA, Holds DJ, Horsfall DJ, Tilley WD. Androgen receptor agonist activity of the synthetic progestin, medroxyprogesterone acetate in human breast cancer cells. Mol Cell Endocrinol 1999; 154: 11-20.
31. Stendahl M, Rydén L, Nordenskjöld B, Jönsson PE, Landberg G, Jirström K. High progesterone receptor expression correlates to the effect of adjuvant tamoxifen in premenopausal breast cancer patients. Clin Cancer Res 2006; 12: 4614-4618.
32. Arpino G, Weiss H, Lee AV, Schiff R, De Placido S, Osborne CK, et al. Estrogen receptor-positive, progesterone receptornegative breast cancer: Association with growth factor receptor expression and tamoxifen resistance. J Natl Cancer Inst 2005; 97: 1254-1261.
33. Dowsett M, Allred C, Knox J, Quinn E, Salter J, Wale C, et al. Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial. J Clin Oncol 2008; 26: 1059-1065.
34. Nahleh ZA. Hormonal therapy for male breast cancer: a different approach for a different disease. Cancer Treat Rev 2006; 32: 101-105.
35. Maddox WA, Carpenter JT Jr, Laws HL, Soong SJ, Cloud G, Urist MM, et al. A randomized prospective trial of radical (Halsted) mastectomy versus modified radical mastectomy in 311 breast cancer patients. Ann Surg 1983; 198: 207-212.
36. Turner L, Swindell R, Bell WG, Hartley RC, Tasker JH, Wilson WW, et al. Radical versus modified radical mastectomy for breast cancer. Ann R Coll Surg Engl 1981; 63: 239-243.
37. Veronesi U, Banfi A, Del Vecchio M, Saccozzi R, Clemente C, Greco M, et al. Comparison of Halsted mastectomy with quadrantectomy, axillary dissection, and radiotherapy in early breast cancer: long-term results. Eur J Cancer Clin Oncol 1986; 22: 1085-1089.
38. Fisher B, Redmond C, Fisher ER, Ten-year results of a randomized clinical trial comparing radical mastectomy and total mastectomy with or without radiation. N Engl J Med 1985; 312: 674-681